Author

G. Bayshtok

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1 Approach:statistical model· 1

Frequent Co-Authors

D. Li· 2 shared P. Chi· 2 shared Y. Chen· 2 shared A. Gopalan· 1 shared A. J. Patel· 1 shared C. J. Lee· 1 shared C. R. Antonescu· 1 shared D. Zheng· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. Li

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BET inhibitors as a therapeutic intervention in gastrointestinal gene signature-positive castration-resistant prostate cancer.

S. Shukla, D. Li, H. Nguyen, J. Conner, G. Bayshtok, W. H. Cho, M. Pachai, N. Teri, E. Campeau, S. Attwell, P. Trojer, I. Ostrovnaya, A. Gopalan, E. Corey, P. Chi, Y. Chen

This study identifies BET inhibitors as effective against GI transcriptome-positive CRPC by targeting HNF1A and HNF4G, improving outcomes in preclinical models.

bioRxiv · Mar 9, 2024 · PreprintCancer Biology

PRC2 Inactivating Mutations in Cancer are Synthetic Lethal with DNMT1 Targeted Therapy via Enhanced Viral Mimicry

A. J. Patel, S. Warda, J. L. V. Maag, R. Misra, M. A. Miranda-Roman, M. R. Pachai, C. J. Lee, D. Li, N. Wang, G. Bayshtok, Y. Meng, E. W. P. Wong, J. Yan, E. Giff, M. B. Pappalardi, , P. Chi

This paper identifies synthetic lethality between PRC2 inactivation and DNMT1 inhibition in MPNST, showing enhanced cytotoxicity through retrotransposon activation and innate immune signaling.

bioRxiv · May 28, 2022 · PreprintCancer Biology